Mark Cooper

Articles in Scholarly Journals [Incomplete List]

  1. The emerging role of ACE2 in physiology and disease
    The Journal of Pathology, vol. 212, no. 1, pp. 1–11, 2007
  2. Plasminogen activator inhibitor-1 production is pathogenetic in experimental murine diabetic renal disease
    Diabetologia, vol. 50, no. 6, pp. 1315–1326, 2007
  3. AGE, RAGE, and ROS in Diabetic Nephropathy
    Seminars in Nephrology, vol. 27, no. 2, pp. 130–143, 2007
  4. Diabetic Nephropathy: Where Hemodynamics Meets Metabolism
    Experimental and Clinical Endocrinology & Diabetes, vol. 115, no. 2, pp. 69–84, 2007
  5. Renal Microvascular Injury in Diabetes: RAGE and Redox Signaling
    Antioxidants & Redox Signaling, vol. 9, no. 3, pp. 331–342, 2007
  6. Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies
    Journal of Hypertension, vol. 25, no. 4, p. 871???876, 2007
  7. Lack of the Antioxidant Enzyme Glutathione Peroxidase-1 Accelerates Atherosclerosis in Diabetic Apolipoprotein E-Deficient Mice
    Circulation, vol. 115, no. 16, pp. 2178–2187, 2007
  8. Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial
    Journal of the American Society of Nephrology, vol. 18, no. 5, pp. 1540–1546, 2007
  9. Connective Tissue Growth Factor Plays an Important Role in Advanced Glycation End Product-Induced Tubular Epithelial-to-Mesenchymal Transition: Implications for Diabetic Renal Disease
    Journal of the American Society of Nephrology, vol. 17, no. 9, pp. 2484–2494, 2006
  10. Advanced Glycation End Products Inhibit Tubulogenesis and Migration of Kidney Epithelial Cells in an Ezrin-Dependent Manner
    Journal of the American Society of Nephrology, vol. 17, no. 2, pp. 414–421, 2006
  11. Combination Therapy with the Advanced Glycation End Product Cross-Link Breaker, Alagebrium, and Angiotensin Converting Enzyme Inhibitors in Diabetes: Synergy or Redundancy?
    Endocrinology, vol. 148, no. 2, pp. 886–895, 2006
  12. Efficacy and Safety of Angiotensin II Receptor Blockade in Elderly Patients With Diabetes
    Diabetes Care, vol. 29, no. 10, pp. 2210–2217, 2006
  13. Is diabetic nephropathy disappearing from clinical practice?
    Pediatric Diabetes, vol. 7, no. 5, pp. 237–238, 2006
  14. Mechanisms of Diabetic Nephropathy: Role of Hypertension
    Hypertension, vol. 48, no. 4, pp. 519–526, 2006
  15. Preventing diabetes in patients with hypertension: one more reason to block the renin???angiotensin system
    Journal of Hypertension, vol. 24, no. Suppl 1, p. S57???S63, 2006
  16. PPAR-  and -  agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse
    Nephrology Dialysis Transplantation, vol. 21, no. 9, pp. 2399–2405, 2006
  17. Developmental expression of ACE2 in the SHR kidney: A role in hypertension?
    Kidney International, vol. 70, no. 1, Article ID 5000428, 7 pages, 2006
  18. Hypertension and Diabetes: Role of the Renin-Angiotensin System
    Endocrinology & Metabolism Clinics of North America, vol. 35, no. 3, pp. 469–490, 2006
  19. Renoprotective effects of renin-angiotensin-system inhibitors
    The Lancet, vol. 367, no. 9514, pp. 899–900, 2006
  20. Role of the renin–angiotensin system in the endocrine pancreas: Implications for the development of diabetes
    The International Journal of Biochemistry & Cell Biology, vol. 38, no. 5-6, pp. 737–751, 2006
  21. Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation
    Diabetologia, vol. 49, no. 4, pp. 766–774, 2006
  22. Anaemia in diabetes: is there a rationale to TREAT?
    Diabetologia, vol. 49, no. 6, pp. 1151–1157, 2006
  23. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study
    Clinical and Experimental Nephrology, vol. 10, no. 3, pp. 193–200, 2006
  24. Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study
    Diabetologia, vol. 48, no. 10, pp. 1980–1987, 2005
  25. Polymorphisms in the gene encoding angiotensin I converting enzyme 2 and diabetic nephropathy
    Diabetologia, vol. 48, no. 11, pp. 2278–2281, 2005
  26. Anemia With Impaired Erythropoietin Response in Diabetic Patients
    Archives of Internal Medicine, vol. 165, no. 4, pp. 466–469, 2005
  27. Diabetes induces Na/H exchange activity and hypertrophy of rat mesenteric but not basilar arteries
    Diabetes Research and Clinical Practice, vol. 70, no. 3, pp. 201–208, 2005
  28. Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease
    American Heart Journal, vol. 149, no. 3, pp. 408–413, 2005
  29. Lipids and diabetic renal disease
    Current Diabetes Reports, vol. 5, no. 6, pp. 445–448, 2005
  30. Advanced-glycation end products in insulin-resistant states
    Current Hypertension Reports, vol. 7, no. 2, pp. 96–102, 2005
  31. Tubular changes in early diabetic nephropathy
    Advances in Chronic Kidney Disease, vol. 12, no. 2, pp. 177–186, 2005
  32. Poor prognosis in proteinuric type 2 diabetic patients with retinopathy: insights from the RENAAL study
    QJM, vol. 98, no. 2, pp. 119–126, 2005
  33. Myocardial infarction increases ACE2 expression in rat and humans
    European Heart Journal, vol. 26, no. 4, pp. 369–375, 2005
  34. Myocardial infarction increases ACE2 expression in rat and humans
    European Heart Journal, vol. 26, no. 11, pp. 1141–1141, 2005
  35. Advanced Glycation End Products and Diabetic Nephropathy
    American Journal of Therapeutics, vol. 12, no. 6, pp. 562–572, 2005
  36. Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes
    Journal of Hypertension, vol. 23, no. 1, pp. 153–164, 2005
  37. Rosiglitazone Attenuates Atherosclerosis in a Model of Insulin Insufficiency Independent of Its Metabolic Effects
    Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 9, pp. 1903–1909, 2005
  38. Targets to retard the progression of diabetic nephropathy
    Kidney International, vol. 68, no. 4, Article ID 4494745, 6 pages, 2005
  39. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2
    Gut, vol. 54, no. 12, pp. 1790–1796, 2005
  40. Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease
    Nephrology, vol. 10, no. 2, pp. 167–173, 2005
  41. The Role of AGEs and AGE Inhibitors in Diabetic Cardiovascular Disease
    Current Drug Targets, vol. 6, no. 4, pp. 453–474, 2005
  42. Agents in development for the treatment of diabetic nephropathy
    Expert Opinion on Investigational Drugs, vol. 14, no. 3, pp. 279–294, 2005
  43. High glucose-induced impairment in insulin secretion is associated with reduction in islet glucokinase in a mouse model of susceptibility to islet dysfunction
    Journal of Molecular Endocrinology, vol. 35, no. 1, pp. 39–48, 2005
  44. Imatinib Attenuates Diabetic Nephropathy in Apolipoprotein E-Knockout Mice
    Journal of the American Society of Nephrology, vol. 16, no. 2, pp. 363–373, 2005
  45. Interactions between Renin Angiotensin System and Advanced Glycation in the Kidney
    Journal of the American Society of Nephrology, vol. 16, no. 10, pp. 2976–2984, 2005
  46. Modulation of Soluble Receptor for Advanced Glycation End Products by Angiotensin-Converting Enzyme-1 Inhibition in Diabetic Nephropathy
    Journal of the American Society of Nephrology, vol. 16, no. 8, pp. 2363–2372, 2005
  47. Localization of the Ezrin Binding Epitope for Glycated Proteins
    Annals of the New York Academy of Sciences, vol. 1043, no. 1, pp. 617–624, 2005
  48. Low-Molecular Weight Advanced Glycation End Products: Markers of Tissue AGE Accumulation and More?
    Annals of the New York Academy of Sciences, vol. 1043, no. 1, pp. 644–654, 2005
  49. Can Advanced Glycation End Product Inhibitors Modulate More than One Pathway to Enhance Renoprotection in Diabetes?
    Annals of the New York Academy of Sciences, vol. 1043, no. 1, pp. 750–758, 2005
  50. Effects of Advanced Glycation End Products on Ezrin-Dependent Functions in LLC-PK1 Proximal Tubule Cells
    Annals of the New York Academy of Sciences, vol. 1043, no. 1, pp. 609–616, 2005
  51. Retinal Expression of Vascular Endothelial Growth Factor Is Mediated by Angiotensin Type 1 and Type 2 Receptors
    Hypertension, vol. 43, no. 2, pp. 276–281, 2004
  52. Advanced Glycation: How are we Progressing to Combat this Web of Sugar Anomalies in Diabetic Nephropathy
    Current Pharmaceutical Design, vol. 10, no. 27, pp. 3361–3372, 2004
  53. Attenuation of Extracellular Matrix Accumulation in Diabetic Nephropathy by the Advanced Glycation End Product Cross-Link Breaker ALT-711 via a Protein Kinase C- -Dependent Pathway
    Diabetes, vol. 53, no. 11, pp. 2921–2930, 2004
  54. Improved Islet Morphology after Blockade of the Renin- Angiotensin System in the ZDF Rat
    Diabetes, vol. 53, no. 4, pp. 989–997, 2004
  55. Advanced Glycation End Product Interventions Reduce Diabetes-Accelerated Atherosclerosis
    Diabetes, vol. 53, no. 7, pp. 1813–1823, 2004
  56. Renin Angiotensin Aldosterone System Blockade and Renal Disease in Patients With Type 2 Diabetes: An Asian perspective from the RENAAL study
    Diabetes Care, vol. 27, no. 4, pp. 874–879, 2004
  57. Diabetic renal disease: from recent studies to improved clinical practice
    Diabetic Medicine, vol. 21, no. 1, pp. 4–17, 2004
  58. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria
    Diabetic Medicine, vol. 21, no. 11, pp. 1192–1199, 2004
  59. Dual blockade of the renin-angiotensin system in diabetic nephropathy
    Diabetic Medicine, vol. 21, no. s1, pp. 15–18, 2004
  60. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL
    Kidney International, vol. 65, no. 6, pp. 2309–2320, 2004
  61. Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes
    Kidney International, vol. 66, no. 3, pp. 1090–1098, 2004
  62. Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes
    Kidney International, vol. 66, no. 3, pp. 1167–1172, 2004
  63. The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes
    Kidney International, vol. 66, no. s92, pp. S105–S107, 2004
  64. The Role of Advanced Glycation in Reduced Organic Cation Transport Associated with Experimental Diabetes
    Journal of Pharmacology and Experimental Therapeutics, vol. 311, no. 2, pp. 456–466, 2004
  65. A Study of VEGF and Its Receptors in Two Rat Models of Proteinuria
    Nephron Physiology, vol. 96, no. 1, pp. p26–p36, 2004
  66. Imatinib Attenuates Diabetes-Associated Atherosclerosis
    Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 5, pp. 935–942, 2004
  67. Irbesartan but Not Amlodipine Suppresses Diabetes-Associated Atherosclerosis
    Circulation, vol. 109, no. 12, pp. 1536–1542, 2004
  68. Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy
    Circulation, vol. 110, no. 8, pp. 921–927, 2004
  69. New insights into the significance of microalbuminuria
    Current Opinion in Nephrology and Hypertension, vol. 13, no. 1, pp. 83–91, 2004
  70. Heparanase Is Involved in the Pathogenesis of Proteinuria as a Result of Glomerulonephritis
    Journal of the American Society of Nephrology, vol. 15, no. 1, pp. 68–78, 2004
  71. Accelerated Nephropathy in Diabetic Apolipoprotein E-Knockout Mouse: Role of Advanced Glycation End Products
    Journal of the American Society of Nephrology, vol. 15, no. 8, pp. 2125–2138, 2004
  72. Interactions between Angiotensin II and NF- B-Dependent Pathways in Modulating Macrophage Infiltration in Experimental Diabetic Nephropathy
    Journal of the American Society of Nephrology, vol. 15, no. 8, pp. 2139–2151, 2004
  73. Identification of angiotensin converting enzyme 2 in the rodent retina
    Current Eye Research, vol. 29, no. 6, pp. 419–427, 2004
  74. Cardiorenal Protective Effects of Vasopeptidase Inhibition with Omapatrilat in Hypertensive Transgenic (mREN-2)27 Rats
    Clinical and Experimental Hypertension, vol. 26, no. 1, pp. 69–80, 2004
  75. Antiproteinuric effect of RAS blockade: New mechanisms
    Current Hypertension Reports, vol. 6, no. 5, pp. 383–392, 2004
  76. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications
    American Journal of Hypertension, vol. 17, pp. S16–S20, 2004
  77. Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease
    American Journal of Hypertension, vol. 17, no. 12, pp. S31–S38, 2004
  78. ACE2, a new regulator of the renin–angiotensin system
    Trends in Endocrinology and Metabolism, vol. 15, no. 4, pp. 166–169, 2004
  79. Novel hexad repeats conserved in a putative transporter with restricted expression in cell types associated with growth, calcium exchange and homeostasis
    Experimental Cell Research, vol. 293, no. 1, pp. 31–42, 2004
  80. Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat
    Diabetologia, vol. 47, no. 1, pp. 89–97, 2004
  81. EASD News Section April 2004
    Diabetologia, vol. 47, no. 4, pp. R35–R48, 2004
  82. ?to: Davis BJ, Forbes JM, Thomas MC et al. (2004) Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Diabetologia 47:89?97
    Diabetologia, vol. 47, no. 8, 2004
  83. Use of genetic mouse models in the study of diabetic nephropathy
    Current Atherosclerosis Reports, vol. 6, no. 3, pp. 197–202, 2004
  84. Microalbuminuria and diabetic cardiovascular disease
    Current Atherosclerosis Reports, vol. 5, no. 5, pp. 350–357, 2003
  85. Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy
    Diabetologia, vol. 46, no. 7, pp. 961–971, 2003
  86. Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease
    Archives of Biochemistry and Biophysics, vol. 419, no. 1, pp. 55–62, 2003
  87. Tranilast attenuates vascular hypertrophy, matrix accumulation and growth factor overexpression in experimental diabetes
    Diabetes & Metabolism, vol. 29, no. 4, pp. 386–392, 2003
  88. The Amino-terminal Domains of the Ezrin, Radixin, and Moesin (ERM) Proteins Bind Advanced Glycation End Products, an Interaction That May Play a Role in the Development of Diabetic Complications
    Journal of Biological Chemistry, vol. 278, no. 28, pp. 25783–25789, 2003
  89. Reduced tubular cation transport in diabetes: Prevented by ACE inhibition
    Kidney International, vol. 63, no. 6, pp. 2152–2161, 2003
  90. Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes
    Kidney International, vol. 64, no. 2, pp. 565–571, 2003
  91. Calcitonin receptor isoforms expressed in the developing rat kidney
    Kidney International, vol. 63, no. 2, pp. 416–426, 2003
  92. Induction of MIF synthesis and secretion by tubular epithelial cells: A novel action of angiotensin II
    Kidney International, vol. 63, no. 4, pp. 1265–1275, 2003
  93. Dialysis delayed is death prevented: A clinical perspective on the RENAAL study
    Kidney International, vol. 63, no. 4, pp. 1577–1579, 2003
  94. Interactions between growth factors in the kidney: Implications for progressive renal injury
    Kidney International, vol. 63, no. 4, pp. 1584–1585, 2003
  95. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin?angiotensin system
    Clinical Science, vol. 104, no. 4, p. 341, 2003
  96. Journal of Hypertension, vol. 21, no. 1, pp. 209–216, 2003
  97. Increased Renal Vascular Endothelial Growth Factor and Angiopoietins by Angiotensin II Infusion Is Mediated by Both AT1 and AT2 Receptors
    Journal of the American Society of Nephrology, vol. 14, no. 12, pp. 3061–3071, 2003
  98. Amylin in the Periphery
    TheScientificWorldJOURNAL, vol. 3, pp. 163–175, 2003
  99. Does vascular endothelial growth factor (VEGF) play a role in the pathogenesis of minimal change disease?
    Nephrology Dialysis Transplantation, vol. 18, no. 11, pp. 2293–2299, 2003
  100. Characterization of Renal Angiotensin-Converting Enzyme 2 in Diabetic Nephropathy
    Hypertension, vol. 41, no. 3, pp. 392–397, 2003
  101. A Breaker of Advanced Glycation End Products Attenuates Diabetes-Induced Myocardial Structural Changes
    Circulation Research, vol. 92, no. 7, pp. 785–792, 2003
  102. Connective Tissue Growth Factor Is Up-Regulated in the Diabetic Retina: Amelioration by Angiotensin-Converting Enzyme Inhibition
    Endocrinology, vol. 145, no. 2, pp. 860–866, 2003
  103. Renal Connective Tissue Growth Factor Induction in Experimental Diabetes Is Prevented by Aminoguanidine
    Endocrinology, vol. 143, no. 12, pp. 4907–4915, 2002
  104. Reduction of the Accumulation of Advanced Glycation End Products by ACE Inhibition in Experimental Diabetic Nephropathy
    Diabetes, vol. 51, no. 11, pp. 3274–3282, 2002
  105. ALT-946 and Aminoguanidine, Inhibitors of Advanced Glycation, Improve Severe Nephropathy in the Diabetic Transgenic (mREN-2)27 Rat
    Diabetes, vol. 51, no. 11, pp. 3283–3289, 2002
  106. Errata
    Diabetes, vol. 51, no. 12, pp. 3592–3592, 2002
  107. A Low-Sodium Diet Potentiates the Effects of L